The January 6, 2015 issue of Cell Metabolism offered exciting news regarding the fight against obesity. Mirabegron, an FDA approved drug for treating overactive bladder, appears to be a viable option for combatting obesity as well. The secret is in Mirabegron’s ability to metabolize brown fat, which generates heat by burning energy, which fights obesity.[…]
Is Mirabegron the Next Treatment to Combat Obesity?
Antispasticity Agent, Blood Glucose Regulator, Drug Research & Development API, FDA Approved 2012 Tags: overactive bladder Jan 13, 2015
Canada Approves Teriflunomide for Multiple Sclerosis
Anti-Inflammatory, Drug Research & Development API, FDA Approved 2012, Health Canada Approved 2013 Tags: multiple sclerosisrelapsing remitting multiple sclerosisRRMS Dec 06, 2013
On November 22, 2013 Health Canada approved the novel once daily pill Teriflunomide for the treatment of Multiple Sclerosis. Approved by the FDA in September of 2012, this efficacious drug is targeted for treating patients with relapsing remitting multiple sclerosis, or RRMS. The ease of use for this 14 milligram pill, taken only once a[…]
Mirabegron for OAB Now Available in Canada
Antispasticity Agent, Drug Research & Development API, FDA Approved 2012, Patent Expiration 2018 Tags: anticholinergicoveractive bladder Aug 14, 2013
Canadian Patients got good news on April 10, 2013 when the availability of Mirabegron for OAB (Overactive Bladder) was announced. “Now that Myrbetriq is available through pharmacies, Canadian patients have access to the first new class of medication for the treatment of OAB in over 30 years,” said Michael Tremblay, President, Astellas Pharma Canada, Inc. Astellas[…]
New Data Touts Value of Apixaban
Antithrombotic, Drug Research & Development API, FDA Approved 2012 Tags: anticoagulantatrial fibrillationWarfarin Jul 29, 2013
Exemplary news on July 1, 2013 revealed that Apixaban, known as the brand name Eliquis, had achieved its primary goal in studies. Marketed by both Pfizer and Bristol-Myers Squibb, Apixaban is an effective anticoagulant that has undergone strenuous testing, based on data from a recently released study coined AMPLIFY. Results from this comprehensive study were[…]
Etravirine Remains a Formidable Treatment for AIDS
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, FDA Approved 2012, Patent Expiration 2019 Tags: AIDSHIV virus Jul 01, 2013
As a successful nonnucleoside reverse transcriptase inhibitor, Etravirine, CAS number 269055-15-4 is also known as the brand name Intelence. With the patent for Intelence set to expire for Janssen on November 5, 2019, additional research and development offering generic formulations of this effectual treatment for AIDS is sure to proliferate. Last year Etravirine was approved[…]
Pazopanib – Two FDA Approvals, Many Impressive Results
Chemotherapeutic / Anti-Neoplastic, FDA Approved 2009, FDA Approved 2012 Tags: chemotherapy Dec 17, 2012
Pazopanib, CAS number 635702-64-6, is an efficacious treatment for patients with advanced renal cell carcinoma, or RCC. As a type of cancer that begins in the cells of the kidneys, mainly in adults, Pazopanib is a reliable treatment in the class of medications called tyrosine kinase inhibitors. Pazopanib works by stopping or slowing the spread[…]
Adalimumab FDA Approved For Moderate to Severe Ulcerative Colitis
FDA Approval News, FDA Approved 2012, Monoclonal Antibodies / mAb Tags: 331731-18-1AdalimumabHumira Sep 28, 2012
On Friday (09-28-12) the FDA announced Adalimumab CAS# 331731-18-1 has been approved to treat moderate to severe ulcerative colitis, for those who are unresponsive to corticosteroids or immunosuppressants. News of the approval comes as the FDA cites the two clinical trials with positive outcomes, involving 908 ulcerative colitis patients. “Results from both studies showed 16.5%[…]
